COBENFY IS NOT A GOOD DRUG

Quote











anonymous said:
I thought the launch was going really well.
Huge growth this year already.
Click to expand...
Growing faster than any other branded product in the same stage of launch. Vraylar, Rexulti and Caplyta all tanking hard on schizophrenia NBRx prescriptions. Seeing cannibalization of other brands was not expected. We thought it would all come from generic. I'd say we are doing pretty good. Analysts agree and predict $4BB a year at peak.

Keep wishing for failure though. It's so much more fun to be miserable.
 


anonymous said:
I thought the launch was going really well.
Huge growth this year already.
Click to expand...
By the way, I was agreeing with you. My final comment was directed at the people rooting for our failure.

If you worked in the schizophrenia space for any period of time, you would know that Cobenfy, overall, is doing very well and helping a lot of patients.
 




Go ahead take every schizophrenia script actually, Vraylar caplyta and rexulti will still run circles around cobenfy. Btw good luck getting a schizophrenic patient to take a pill BID, they already have a 74% non adherence rate.
 


BID my dude, BID. So many other schizophrenic meds to choose from and why would a family member, who are hugely involved in the decision making process, choose BID over the many other more disease friendly dosing options? Massive hurdle that will soon be seen as growth stunts.
 




anonymous said:
BID my dude, BID. So many other schizophrenic meds to choose from and why would a family member, who are hugely involved in the decision making process, choose BID over the many other more disease friendly dosing options? Massive hurdle that will soon be seen as growth stunts.
Click to expand...
Patients with schizophrenia need something new. The D2 story has been told over and over and over again. Some meds are better than others but none are truly different. Cobenfy offers hope for patients who already cycled through multiple D2 therapies. GI side effects with Cobenfy may be a challenge but nothing compared to TD and EPS, weight gain and cardiovascular risk and mortality. The PI is great. No boxed warnings! Off the charts efficacy. If you’ve been in the psych space for any length of time, you know this is a big deal.

BID dosing is not an issue for patients who are used to taking handfuls of meds multiple times a day.
 


anonymous said:
Go ahead take every schizophrenia script actually, Vraylar caplyta and rexulti will still run circles around cobenfy. Btw good luck getting a schizophrenic patient to take a pill BID, they already have a 74% non adherence rate.
Click to expand...
How will you feel when we start to take away the scripts for other indications? Because that’s coming.
 













Write your reply...
Top Bottom
Back
Quote